Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Atara Biotherapeutics, Inc. operates as a biotechnology company. The Company focuses on developing therapies for patients with severe and life-threatening diseases.
Website: atarabio.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 89.6%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -331.9%. On average the margin is improving steadily. Gross margin is high, +100.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of +$0.13 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -27.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 3 916.5% higher than minimum and 48.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 6.4x by EV / Sales multiple , the company can be 64.4% overvalued

Key Financials (Download financials)

Ticker: ATRA
Share price, USD:  (0.0%)9.23
year average price 8.63  


year start price 0.52 2024-06-10

min close price 0.39 2024-06-18

max close price 18.00 2025-01-06

current price 9.23 2025-06-09
Common stocks: 140 587 000

Dividend Yield:  0.0%
EV / Sales: 17.9x
Margin (EBITDA LTM / Revenue): -331.9%
Fundamental value created in LTM:
Market Cap ($m): 1 298
Net Debt ($m): -7
EV (Enterprise Value): 1 291
Price to Book: -14.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-16businesswire.com

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

2025-05-15businesswire.com

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

2025-03-13zacks.com

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade

2025-03-07zacks.com

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

2025-02-22accessnewswire.com

An Investigation Has Been Launched Into Atara Biotherapeutics, Inc. For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm

2025-02-17accessnewswire.com

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

2025-02-14prnewswire.com

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

2025-02-13accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

2025-02-11prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

2025-02-11accessnewswire.com

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATRA ATRA ATRA ATRA ATRA ATRA ATRA ATRA ATRA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-12 2024-05-09 2024-03-28 2023-11-01 2023-08-08 2023-05-08 2023-02-08 2022-11-08
acceptedDate 2024-11-12 16:10:25 2024-08-12 17:10:21 2024-05-09 16:11:14 2024-03-28 08:40:41 2023-11-01 08:40:29 2023-08-08 16:13:09 2023-05-08 16:14:23 2023-02-08 16:54:50 2022-11-08 16:20:01
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 40M 29M 27M 4M 2M 957 000 1M 221 000 4M
costOfRevenue 8M 5M 2M 3M 3M 3M 216 000 0 0
grossProfit 33M 24M 25M 1M -477 000 -2M 1M 221 000 4M
grossProfitRatio 0.811 0.838 0.927 0.257 -0.223 -2.025 0.824 1 1
researchAndDevelopmentExpenses 44M 33M 42M 44M 57M 56M 62M 63M 70M
generalAndAdministrativeExpenses 10M 9M 11M 11M 12M 13M 14M 13M 19M
sellingAndMarketingExpenses 0 0 -1M -1M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 10M 9M 10M 10M 12M 13M 14M 13M 19M
otherExpenses 0 0 68 000 -12 000 -27 000 -10000 -197 000 0 0
operatingExpenses 54M 42M 52M 54M 69M 69M 76M 76M 89M
costAndExpenses 62M 47M 54M 58M 72M 72M 76M 76M 89M
interestIncome 459 000 450 000 604 000 711 000 1M 2M 269 000 0 0
interestExpense 1M 1M 1M 1M 1M 1M 1M 969 000 541 000
depreciationAndAmortization 1M 1M 1M 1M 1M 1M 1M 1M 1M
ebitda -20M -16M -25M -52M -67M -69M -75M -76M -83M
ebitdaratio -0.486 -0.575 -0.918 -12.246 -31.437 -71.607 -61.189 -341.805 -18.671
operatingIncome -22M -18M -26M -53M -70M -71M -75M -76M -85M
operatingIncomeRatio -0.541 -0.637 -0.969 -12.53 -32.559 -74.623 -61.189 -341.805 -18.978
totalOtherIncomeExpensesNet -169 000 -818 000 -5M -7M -27 000 -10000 269 000 969 000 541 000
incomeBeforeTax -22M -19M -32M -60M -70M -71M -75M -75M -84M
incomeBeforeTaxRatio -0.546 -0.665 -1.16 -14.214 -32.655 -74.302 -60.97 -337.421 -18.856
incomeTaxExpense -17 000 0 24 000 11 000 -19 000 1000 22 000 2000 10000
netIncome -22M -19M -318M -60M -70M -71M -75M -75M -84M
netIncomeRatio -0.545 -0.665 -11.607 -14.217 -32.646 -74.303 -60.988 -337.43 -18.859
eps -2.93 -3.1 -5.75 -0.56 -0.66 -0.68 -0.72 -0.72 -0.82
epsdiluted -2.93 -3.1 -5.65 -0.56 -0.66 -0.68 -0.72 -0.72 -0.82
weightedAverageShsOut 7M 6M 55M 108M 106M 105M 104M 103M 102M
weightedAverageShsOutDil 7M 6M 56M 108M 106M 105M 104M 103M 102M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATRA ATRA ATRA ATRA ATRA ATRA ATRA ATRA ATRA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-12 2024-05-09 2024-03-28 2023-11-01 2023-08-08 2023-05-08 2023-02-08 2022-11-08
acceptedDate 2024-11-12 16:10:25 2024-08-12 17:10:21 2024-05-09 16:11:14 2024-03-28 08:40:41 2023-11-01 08:40:29 2023-08-08 16:13:09 2023-05-08 16:14:23 2023-02-08 16:54:50 2022-11-08 16:20:01
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 46M 31M 35M 26M 65M 46M 49M 93M 65M
shortTermInvestments 21M 4M 11M 26M 38M 108M 157M 150M 200M
cashAndShortTermInvestments 67M 35M 46M 52M 102M 154M 205M 243M 265M
netReceivables 1M 2M 36M 34M 163 000 507 000 397 000 40M 249 000
inventory 14M 19M 16M 10M 7M 8M 5M 2M 0
otherCurrentAssets 9M 6M 8M 6M 9M 10M 13M 10M 17M
totalCurrentAssets 92M 62M 106M 102M 119M 172M 224M 295M 283M
propertyPlantEquipmentNet 47M 51M 55M 59M 64M 68M 71M 74M 78M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 3M 4M 4M 5M 6M 7M 7M 7M 7M
totalNonCurrentAssets 51M 55M 59M 64M 70M 74M 78M 81M 85M
otherAssets 0 0 1 1 0 0 0 0 0
totalAssets 143M 117M 165M 166M 189M 246M 302M 376M 368M
accountPayables 2M 5M 3M 4M 7M 4M 5M 7M 11M
shortTermDebt 15M 14M 15M 12M 13M 13M 0 14M 0
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 116M 108M 123M 78M 12M 12M 10M 8M 3M
otherCurrentLiabilities 23M 21M 40M 49M 48M 46M 53M 50M 58M
totalCurrentLiabilities 156M 148M 181M 142M 79M 75M 68M 79M 72M
longTermDebt 35M 75M 36M 46M 49M 52M 55M 58M 61M
deferredRevenueNonCurrent 0 567 000 719 000 38M 74M 76M 78M 77M 42M
deferredTaxLiabilitiesNonCurrent 0 -36M -1 0 33M 32M 0 0 0
otherNonCurrentLiabilities 42M 4M 47M 39M 5M 5M 36M 36M 95M
totalNonCurrentLiabilities 77M 80M 83M 123M 161M 164M 169M 171M 109M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 50M 53M 42M 46M 62M 65M 55M 58M 61M
totalLiabilities 233M 228M 264M 265M 240M 239M 237M 250M 181M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 1000 0 12 000 11 000 10000 10000 10000 10000 9000
retainedEarnings -2 042M -2 020M -2 001M -1 969M -1 909M -1 839M -1 768M -1 693M -1 618M
accumulatedOtherComprehensiveIncomeLoss 22 000 -14 000 -55 000 -204 000 -571 000 -933 000 -1M -2M -3M
othertotalStockholdersEquity 1 951M 1 909M 1 903M 1 870M 1 858M 1 847M 1 834M 1 822M 1 809M
totalStockholdersEquity -91M -111M -98M -99M -51M 7M 65M 127M 187M
totalEquity -91M -111M -98M -99M -51M 7M 65M 127M 187M
totalLiabilitiesAndStockholdersEquity 143M 117M 165M 166M 189M 246M 302M 376M 368M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 143M 117M 165M 166M 189M 246M 302M 376M 368M
totalInvestments 21M 4M 11M 26M 38M 108M 157M 150M 200M
totalDebt 50M 53M 92M 58M 62M 65M 55M 72M 61M
netDebt 3M 21M 57M 32M -3M 19M 6M -21M -4M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATRA ATRA ATRA ATRA ATRA ATRA ATRA ATRA ATRA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-12 2024-05-09 2024-03-28 2023-11-01 2023-08-08 2023-05-08 2023-02-08 2022-11-08
acceptedDate 2024-11-12 16:10:25 2024-08-12 17:10:21 2024-05-09 16:11:14 2024-03-28 08:40:41 2023-11-01 08:40:29 2023-08-08 16:13:09 2023-05-08 16:14:23 2023-02-08 16:54:50 2022-11-08 16:20:01
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -22M -19M -32M -60M -70M -71M -75M -75M -84M
depreciationAndAmortization 1M 1M 1M 1M 1M 1M 1M 1M 1M
deferredIncomeTax 0 0 0 -52M -214 000 -755 000 0 0 0
stockBasedCompensation 6M 6M 8M 10M 11M 13M 12M 11M 14M
changeInWorkingCapital 15M -3M -12M -7M 2M 1M 20M 2M 707 000
accountsReceivables 1M 33M -2M -34M 344 000 -110 000 40M -40M 388 000
inventory 5M -3M -6M -3M 1M -3M -4M -2M 0
accountsPayables -3M 2M -826 000 -3M 2M -894 000 -2M -4M -1M
otherWorkingCapital 12M -37M -3M 33M -2M 5M -15M 48M 2M
otherNonCashItems -5M 4M 24M 58M 4M 4M 4M 3M 3M
netCashProvidedByOperatingActivities -4M -11M -30M -50M -51M -53M -38M -57M -65M
investmentsInPropertyPlantAndEquipment 0 -29 000 -127 000 -44 000 -281 000 -499 000 -399 000 -37 000 -132 000
acquisitionsNet 0 0 0 -40M 25 000 -50M 0 0 0
purchasesOfInvestments -20M 0 0 -1000 -25 000 -16M -68M 575 000 -16M
salesMaturitiesOfInvestments 3M 7M 15M 10M 71M 66M 62M 51M 76M
otherInvestingActivites 0 0 15M 40M 25 000 50M 0 0 0
netCashUsedForInvestingActivites -17M 7M 15M 10M 70M 49M -6M 51M 60M
debtRepayment -197 000 -233 000 -227 000 -215 000 -208 000 -212 000 -312 000 -122 000 -206 000
commonStockIssued 51M -15M 24M 2M 0 -50 000 640 000 32M 0
commonStockRepurchased 6000 0 -6000 94 000 0 -1000 0 0 0
dividendsPaid 0 0 0 0 0 -1000 0 0 0
otherFinancingActivites -15M 15M -6000 652 000 652 000 735 000 -93 000 432 000 -8000
netCashUsedProvidedByFinancingActivities 36M -324 000 24M 2M -208 000 471 000 235 000 32M -214 000
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash 15M -4M 9M -39M 19M -3M -44M 27M -6M
cashAtEndOfPeriod 47M 31M 35M 26M 65M 46M 49M 93M 66M
cashAtBeginningOfPeriod 31M 35M 26M 65M 46M 49M 93M 66M 72M
operatingCashFlow -4M -11M -30M -50M -51M -53M -38M -57M -65M
capitalExpenditure 0 -29 000 -127 000 -44 000 -281 000 -499 000 -399 000 -37 000 -132 000
freeCashFlow -4M -11M -30M -50M -52M -53M -39M -57M -65M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2023 q3
2023-11-04 ET (fiscal 2023 q3)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-08 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-08-13 13:30 ET
Sidoti Events, LLC's Virtual August Micro-Cap Conference
2024-08-12 21:00 ET
Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update
2024-08-07 20:01 ET
Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
2024-07-17 13:00 ET
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
2024-07-05 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-07-03 23:57 ET
Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum
2024-06-21 20:01 ET
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
2024-06-17 12:00 ET
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
2024-06-07 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-06-05 20:01 ET
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-29 20:01 ET
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
2024-05-20 13:25 ET
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
2024-05-09 20:01 ET
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
2024-05-03 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-04-05 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-03-28 12:30 ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
2024-02-29 14:05 ET
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
2024-02-28 21:30 ET
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
2024-02-14 14:00 ET
Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
2024-01-31 23:30 ET
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
2024-01-08 14:00 ET
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
2024-01-08 13:00 ET
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-04 21:01 ET
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 21:01 ET
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
2023-12-11 17:00 ET
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
2023-12-01 21:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 23:05 ET
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
2023-11-22 21:01 ET
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
2023-11-10 21:01 ET
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
2023-11-08 22:35 ET
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
2023-11-01 12:30 ET
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
2023-10-06 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-19 20:01 ET
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
2023-09-01 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-08-31 20:01 ET
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
2023-08-08 20:01 ET
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
2023-08-04 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-01 20:01 ET
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
2023-07-31 20:01 ET
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
2023-07-07 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-07 20:01 ET
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-05 13:00 ET
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
2023-06-02 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-08 20:01 ET
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
2023-05-05 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-01 20:01 ET
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
2023-03-31 20:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-03 21:01 ET
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-01 21:01 ET
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
2023-02-21 21:01 ET
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
2023-02-08 21:01 ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
2023-02-08 11:00 ET
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
2023-02-06 13:00 ET
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
2023-02-03 21:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-13 21:01 ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-01-04 21:01 ET
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-20 21:33 ET
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
2022-12-19 13:00 ET
Atara Biotherapeutics Announces Changes to Its Board of Directors
2022-12-19 12:00 ET
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
2022-12-15 21:01 ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-12-12 15:00 ET
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
2022-12-02 21:01 ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-11-23 13:00 ET
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
2022-11-09 21:01 ET
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
2022-11-08 21:01 ET
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
2022-11-04 20:01 ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-11-01 20:05 ET
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
2022-10-26 06:01 ET
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
2022-10-14 11:08 ET
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
2022-10-10 20:01 ET
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2022-09-28 20:01 ET
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
2022-08-31 20:01 ET
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference
2022-08-08 20:01 ET
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
2022-08-04 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-03 20:01 ET
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
2022-08-01 20:01 ET
Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
2022-07-12 20:30 ET
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
2022-07-06 20:01 ET
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
2022-07-01 23:57 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-04 13:00 ET
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress
2022-06-03 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-19 20:01 ET
Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer
2022-05-06 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-05-05 20:01 ET
Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress
2022-04-29 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-28 20:01 ET
Atara Biotherapeutics to Announce First Quarter 2022 Financial Results on Thursday, May 5, 2022
2022-04-22 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-08 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-05 20:01 ET
Atara Biotherapeutics Names Biopharmaceutical Executive Charlene Banard as Chief Technical Officer
2022-04-04 20:01 ET
Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of Long-Term Strategic Partnership with Fujifilm
2022-03-15 20:01 ET
Atara Biotherapeutics to Host EBV and MS Day
2022-03-04 21:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2022-03-02 13:00 ET
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 42nd Annual Virtual Healthcare Conference
2022-02-28 21:05 ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
2022-02-18 13:00 ET
Atara Biotherapeutics Provides Update on ATA2271 Autologous CAR T Trial
2022-02-17 21:01 ET
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
2022-02-07 21:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2022-01-26 21:30 ET
Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
2022-01-24 16:13 ET
New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis
2022-01-10 13:30 ET
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
2022-01-07 21:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-06 15:00 ET
Be The Match BioTherapies® and Atara Biotherapeutics Announce Multi-Year Partnership Extension
2022-01-05 21:01 ET
Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-14 00:15 ET
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
2021-12-09 13:00 ET
Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
2021-12-03 21:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-30 13:30 ET
European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
2021-11-08 21:01 ET
Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
2021-11-05 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-11-04 13:30 ET
Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data
2021-11-04 11:30 ET
Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
2021-10-28 20:01 ET
Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
2021-10-13 11:30 ET
Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021
2021-10-04 11:30 ET
Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)
2021-10-01 22:14 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-09-29 07:30 ET
Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021
2021-09-27 12:30 ET
European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)
2021-09-03 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-09-02 12:30 ET
Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference
2021-08-09 20:02 ET
Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress
2021-08-09 20:01 ET
Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors
2021-08-02 22:00 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-08-02 12:30 ET
Atara Biotherapeutics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
2021-07-02 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-07-01 20:30 ET
Atara Biotherapeutics Joins the Rare Disease Company Coalition Alongside Industry Gamechangers
2021-06-07 14:30 ET
Atara Biotherapeutics Presents Positive Tab-cel® Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect
2021-06-04 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-05-14 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-05-13 20:01 ET
Atara Biotherapeutics to Participate at the Cowen Virtual Oncology Innovation Summit
2021-05-10 12:30 ET
Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer
2021-05-07 20:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-05-04 20:01 ET
Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
2021-04-27 21:51 ET
Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
2021-04-02 20:35 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-03-14 20:00 ET
Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting
2021-03-09 21:01 ET
Atara Biotherapeutics to Participate in Virtual 33rd Annual ROTH Conference
2021-03-05 21:01 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2021-03-01 21:05 ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
2021-02-18 21:01 ET
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
2021-02-08 14:00 ET
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
2021-01-19 21:14 ET
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
2021-01-10 21:06 ET
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
2021-01-06 13:30 ET
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
2021-01-04 12:30 ET
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
2020-12-09 02:26 ET
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
2020-12-07 21:07 ET
Atara Biotherapeutics Announces Proposed Offering of Common Stock
2020-12-07 12:00 ET
Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting
2020-12-07 04:00 ET
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
2020-11-16 21:01 ET
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
2020-11-15 15:00 ET
Atara Biotherapeutics to Present New Open-Label Extension Data, Including 15-Month Safety and Efficacy Data from Highest Dose Cohorts, in the Phase1a Study of ATA188 for Progressive Forms of Multiple Sclerosis at the ECF 28th Annual Meeting
2020-11-12 13:30 ET
Atara Biotherapeutics Presents New Preclinical Data on ATA3271, a Next-Generation Allogeneic Mesothelin-Targeted CAR T to Treat Solid Tumors, at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)
2020-11-09 21:01 ET
Atara Biotherapeutics Announces Third Quarter 2020 Financial Results and Operational Progress
2020-11-02 21:01 ET
Atara Biotherapeutics to Announce Third Quarter 2020 Financial Results on Monday, November 9, 2020
2020-09-14 12:30 ET
Atara Biotherapeutics To Present Clinical Data in Epstein-Barr Virus-Driven (EBV+) Acquired & Primary Immunodeficiency Lymphoproliferative Diseases (AID-LPD and PID-LPD) from Tab-Cel® Expanded Access Program in e-Poster at ESMO 2020 Virtual Congress
2020-09-11 12:00 ET
Atara Biotherapeutics Announces All Progressive Multiple Sclerosis Patients with Sustained Disability Improvement at Six Months Confirmed Improvement at 12 Months in the Phase 1a Study of ATA188
2020-09-08 11:00 ET
Atara Biotherapeutics Announces FDA Clearance of IND for ATA2271, a Next-Generation Autologous Mesothelin-Targeted CAR T with Novel PD1DNR and 1XX Technologies Combined to Treat Solid Tumors
2020-09-01 11:00 ET
Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progressive Multiple Sclerosis at MSVirtual2020
2020-08-05 20:01 ET
Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress
2020-07-29 20:01 ET
Atara Biotherapeutics to Announce Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
2020-06-24 20:34 ET
Atara Biotherapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-06-17 12:47 ET
 Atara Biotherapeutics Announces First Patient Enrolled in Randomized Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of Multiple Sclerosis
2020-06-05 20:15 ET
Atara Biotherapeutics Announces its 2020 Annual Meeting of Stockholders Will Be Held on June 16, 2020 in Virtual Format
2020-06-04 20:01 ET
Atara Biotherapeutics to Participate at Two Upcoming Conferences
2020-05-27 05:16 ET
Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering
2020-05-26 20:05 ET
Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
2020-05-26 11:00 ET
Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress
2020-05-19 12:30 ET
Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress
2020-05-18 20:30 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2020-05-15 13:38 ET
Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research (AACR) Virtual Annual Meeting II 2020
2020-05-14 20:05 ET
 Atara Biotherapeutics Names Cell Therapy & Oncology Leader Jakob Dupont, M.D. as Global Head of Research & Development
2020-05-11 20:01 ET
Atara Biotherapeutics Announces Appointment of Cell & Gene Therapy Expert Maria Grazia Roncarolo, MD to Board of Directors
2020-05-06 20:01 ET
Atara Biotherapeutics Announces First Quarter 2020 Financial Results and Operational Progress
2020-04-30 20:01 ET
Atara Biotherapeutics to Announce First Quarter 2020 Financial Results on Wednesday, May 6, 2020
2020-04-30 12:30 ET
Atara Biotherapeutics Appoints Biotech and Finance Industry Veteran Ron Renaud as Non-Executive Chair of the Board of Directors
2020-04-23 00:30 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2020-04-02 12:33 ET
Company Profile for Atara Biotherapeutics, Inc.
2020-04-02 12:30 ET
Atara Biotherapeutics Provides Update in Context of COVID-19 Pandemic
2020-02-27 12:30 ET
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
2020-02-21 21:00 ET
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2020-02-20 21:00 ET
Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences
2020-02-19 21:00 ET
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020
2020-02-05 13:30 ET
Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer
2020-01-12 19:00 ET
Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference
2019-11-26 21:00 ET
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
2019-11-07 12:30 ET
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
2019-10-30 20:05 ET
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
2019-10-25 22:11 ET
Atara Biotherapeutics Announces Executive Departures
2019-09-13 10:15 ET
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
2019-09-09 12:00 ET
Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

SEC forms

Show financial reports only

SEC form 8
2025-05-15 00:00 ET
Atara Biotherapeutics published news for 2025 q1
SEC form 8
2025-05-15 00:00 ET
Atara Biotherapeutics reported for 2025 q1
SEC form 10
2025-05-15 00:00 ET
Atara Biotherapeutics reported for 2025 q1
SEC form 8
2025-03-07 00:00 ET
Atara Biotherapeutics published news for 2024 q4
SEC form 8
2025-03-07 00:00 ET
Atara Biotherapeutics reported for 2024 q4
SEC form 10
2025-03-07 00:00 ET
Atara Biotherapeutics reported for 2024 q4
SEC form 8
2025-01-16 00:00 ET
Atara Biotherapeutics published news for 2024 q4
SEC form 8
2025-01-16 00:00 ET
Atara Biotherapeutics published news for 2024 q4
SEC form 10
2024-11-12 16:10 ET
Atara Biotherapeutics reported for 2024 q3
SEC form 8
2024-11-12 16:05 ET
Atara Biotherapeutics published news for 2024 q3
SEC form 8
2024-11-12 16:05 ET
Atara Biotherapeutics reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Atara Biotherapeutics reported for 2024 q3
SEC form 10
2024-08-12 17:10 ET
Atara Biotherapeutics reported for 2024 q2
SEC form 8
2024-08-12 00:00 ET
Atara Biotherapeutics published news for 2024 q2
SEC form 8
2024-08-12 00:00 ET
Atara Biotherapeutics published news for 2024 q2
SEC form 8
2024-08-12 00:00 ET
Atara Biotherapeutics published news for 2024 q2
SEC form 10
2024-08-12 00:00 ET
Atara Biotherapeutics reported for 2024 q2
SEC form 8
2024-08-12 00:00 ET
Atara Biotherapeutics reported for 2024 q2
SEC form 8
2024-05-09 00:00 ET
Atara Biotherapeutics published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Atara Biotherapeutics reported for 2024 q1
SEC form 10
2024-05-09 00:00 ET
Atara Biotherapeutics reported for 2024 q1
SEC form 10
2024-03-28 08:40 ET
Atara Biotherapeutics reported for 2023 q4
SEC form 8
2024-03-28 08:35 ET
Atara Biotherapeutics published news for 2023 q4
SEC form 8
2024-03-28 08:35 ET
Atara Biotherapeutics reported for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Atara Biotherapeutics reported for 2023 q4
SEC form 10
2023-11-01 08:40 ET
Atara Biotherapeutics reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Atara Biotherapeutics reported for 2023 q3
SEC form 10
2023-08-08 16:13 ET
Atara Biotherapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:07 ET
Atara Biotherapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Atara Biotherapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Atara Biotherapeutics reported for 2023 q2
SEC form 6
2023-06-09 16:30 ET
Atara Biotherapeutics published news for 2023 q1
SEC form 6
2023-06-09 16:30 ET
Atara Biotherapeutics published news for 2023 q1
SEC form 6
2023-06-09 16:30 ET
Atara Biotherapeutics published news for 2023 q1
SEC form 6
2023-06-09 16:06 ET
Atara Biotherapeutics published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Atara Biotherapeutics reported for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Atara Biotherapeutics reported for 2023 q1
SEC form 10
2023-02-08 00:00 ET
Atara Biotherapeutics reported for 2022 q4
SEC form 8
2023-02-08 00:00 ET
Atara Biotherapeutics reported for 2022 q4
SEC form 10
2022-11-08 00:00 ET
Atara Biotherapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Atara Biotherapeutics reported for 2022 q3
SEC form 10
2022-08-08 00:00 ET
Atara Biotherapeutics reported for 2022 q2
SEC form 8
2022-05-05 00:00 ET
Atara Biotherapeutics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Atara Biotherapeutics reported for 2022 q1
SEC form 8
2022-02-28 00:00 ET
Atara Biotherapeutics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Atara Biotherapeutics published news for 2021 q4
SEC form 8
2021-11-04 00:00 ET
Atara Biotherapeutics published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Atara Biotherapeutics published news for 2021 q3
SEC form 8
2021-08-09 00:00 ET
Atara Biotherapeutics published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Atara Biotherapeutics published news for 2021 q2
SEC form 8
2021-05-04 00:00 ET
Atara Biotherapeutics published news for 2021 q1
SEC form 10
2021-05-04 00:00 ET
Atara Biotherapeutics published news for 2021 q1